BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND PTPRK, DKFZp686C2268, 5796, ENSG00000152894, DKFZp779N1045, R-PTP-kappa, RP3-480J14_1 AND Prognosis
3955 results:

  • 1. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
    Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
    J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: Insights from an in vitro model of collective detachment.
    Micek HM; Yang N; Dutta M; Rosenstock L; Ma Y; Hielsberg C; McCord M; Notbohm J; McGregor S; Kreeger PK
    Sci Adv; 2024 Apr; 10(17):eadl4463. PubMed ID: 38669327
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL-1.
    Cai Y; Li Y; Xu Y; Yang W; Huang M
    FASEB J; 2024 Apr; 38(8):e23625. PubMed ID: 38661028
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
    Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
    J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
    Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
    BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Gonadoblastoma: Clinicopathological study and literature review of 3 cases].
    Bao ML; Li X; Chen G; Li H; Chen W; Li HX
    Zhonghua Nan Ke Xue; 2023 Jul; 29(7):634-638. PubMed ID: 38619412
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Predictive value of red blood cell distribution width and hematocrit for short-term outcomes and prognosis in colorectal cancer patients undergoing radical surgery.
    Peng D; Li ZW; Liu F; Liu XR; Wang CY
    World J Gastroenterol; 2024 Mar; 30(12):1714-1726. PubMed ID: 38617745
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.
    Du Y; Xiao Y; Guo W; Yao J; Lan T; Li S; Wen H; Zhu W; He G; Zheng H; Chen H
    Biomed Eng Online; 2024 Apr; 23(1):41. PubMed ID: 38594729
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Long non-coding RNA RAD51-AS1 promotes the tumorigenesis of ovarian cancer by elevating EIF5A2 expression.
    Zhao L; Huang J; Liu W; Su X; Zhao B; Wang X; He X
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):179. PubMed ID: 38584230
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Relationships of SIGLEC family-related lncRNAs with clinical prognosis and tumor immune microenvironment in ovarian cancer.
    Jin X; Chen Y; Hu Q
    Sci Rep; 2024 Mar; 14(1):7593. PubMed ID: 38556590
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Characteristics of patients with late recurrence endometrial cancer.
    Çakır İ; Gülseren V; Özdemir İA; Abacı H; Talu ECK; Çakır ZE; Ata C; Kuru O; Gökçü M; Sancı M; Güngördük K
    J Cancer Res Ther; 2024 Jan; 20(1):232-237. PubMed ID: 38554326
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
    Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
    Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
    [No Abstract]    [Full Text] [Related]  

  • 14. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate cancer.
    Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
    Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. PURE vs. mixed clear cell ovarian carcinomas: Is there any impact on survival?
    Güzel D; Terek C; Besler A; Serin G; Önal Z; Akman L; Göker E; Ali Şanli U; Zekioğlu O; Özdemir N; Özsaran A; Yildirim N
    Eur J Obstet Gynecol Reprod Biol; 2024 May; 296():321-326. PubMed ID: 38518487
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance.
    Kuang L; Zhang J; Li Y; Wang Q; Liu J; Zhang B
    BMC Womens Health; 2024 Mar; 24(1):188. PubMed ID: 38515066
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
    Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
    Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Paraneoplastic movement disorders.
    McKeon A; Tracy J
    Handb Clin Neurol; 2024; 200():211-227. PubMed ID: 38494279
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.
    Feng S; Ding B; Dai Z; Yin H; Ding Y; Liu S; Zhang K; Lin H; Xiao Z; Shen Y
    J Transl Med; 2024 Mar; 22(1):280. PubMed ID: 38491511
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The analysis of preoperative or intraoperative factors in predicting the escalation of surgical pathological staging of patients with clinical stage I endometrioid carcinoma: A retrospective clinical study.
    Li N; Chen Q; Li B
    Medicine (Baltimore); 2024 Mar; 103(11):e37465. PubMed ID: 38489719
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 198.